Should I buy or sell REGENXBIO stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGNX shares. View RGNX analyst ratings or view top-rated stocks .

What is REGENXBIO's stock price target for 2024?

12 Wall Street research analysts have issued 1-year price objectives for REGENXBIO's shares. Their RGNX share price targets range from $21.00 to $55.00. On average, they anticipate the company's stock price to reach $38.45 in the next year. This suggests a possible upside of 138.7% from the stock's current price. View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts .

How have RGNX shares performed in 2024?

REGENXBIO's stock was trading at $17.95 on January 1st, 2024. Since then, RGNX shares have decreased by 10.3% and is now trading at $16.11. View the best growth stocks for 2024 here .

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our RGNX earnings forecast .

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by $0.16. The biotechnology company earned $22.30 million during the quarter, compared to the consensus estimate of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative trailing twelve-month return on equity of 68.18%. The company's quarterly revenue was down 28.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.38) earnings per share.

What ETFs hold REGENXBIO's stock?

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and WisdomTree BioRevolution Fund (WDNA) . Harbor Disruptive Innovation ETF (INNO) .

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com . Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV) , Micron Technology (MU) , NVIDIA (NVDA) , Voyager Therapeutics (VYGR) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , QUALCOMM (QCOM) , Gilead Sciences (GILD) and Block (SQ) .

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.22%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Allan M Fox , Kenneth T Mills , Kenneth T Mills , Steve Pakola , Vittal Vasista and WR Stephens, Iii 2012 Trust. View institutional ownership trends .

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RGNX

REGENXBIO (RGNX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free RGNX Stock Alerts

$16.11

-0.92 (-5.40%)

(As of 04/18/2024 ET)

Compare

Today's Range: $16.05
▼
$16.81
50-Day Range: $16.04
▼
$24.61
52-Week Range: $11.83
▼
$28.80

Volume: 560,517 shs
Average Volume: 735,784 shs
Market Capitalization: $790.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.45

Get REGENXBIO alerts:

REGENXBIO MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 138.7% Upside
$38.45 Price Target
Short Interest: Bearish
8.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 0.23
Based on 9 Articles This Week
Insider Trading: Selling Shares
$1.22 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.98) to ($3.28) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

82nd out of 918 stocks

Biological Products, Except Diagnostic Industry

9th out of 147 stocks

4.4

Analyst's Opinion

Consensus Rating
REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
REGENXBIO has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
8.05% of the outstanding shares of REGENXBIO have been sold short.
Short Interest Ratio / Days to Cover
REGENXBIO has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in REGENXBIO has recently decreased by 4.82%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
REGENXBIO does not currently pay a dividend.
Dividend Growth
REGENXBIO does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
REGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for REGENXBIO is -0.82.

1.8

News and Social Media Coverage

News Sentiment
REGENXBIO has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for REGENXBIO this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,217,370.00 in company stock.
Percentage Held by Insiders
13.13% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for REGENXBIO are expected to grow in the coming year, from ($3.98) to ($3.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of REGENXBIO is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of REGENXBIO is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
REGENXBIO has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About REGENXBIO Stock (NASDAQ:RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

RGNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RGNX Stock News Headlines

April 18, 2024 | insidertrades.com

Kenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) Stock

March 19, 2024 | insidertrades.com

REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $327,900.00 in Stock

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 19, 2024 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Stock Price Down 3.1% Following Insider Selling

April 17, 2024 | finance.yahoo.com

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures

April 14, 2024 | americanbankingnews.com

REGENXBIO's (RGNX) Buy Rating Reaffirmed at Stifel Nicolaus

April 12, 2024 | markets.businessinsider.com

Where Regenxbio Stands With Analysts

April 11, 2024 | americanbankingnews.com

REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by StockNews.com

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 31, 2024 | benzinga.com

Regenxbio Stock (NASDAQ:RGNX), Quotes and News Summary

March 28, 2024 | finance.yahoo.com

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

March 28, 2024 | prnewswire.com

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

March 27, 2024 | finance.yahoo.com

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

March 18, 2024 | finance.yahoo.com

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares

March 12, 2024 | bizjournals.com

Rockville biotech raises $140M following layoffs, program cuts

March 11, 2024 | seekingalpha.com

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

March 11, 2024 | realmoney.thestreet.com

Regenxbio initiated with bullish view at H.C. Wainwright, here's why

March 11, 2024 | prnewswire.com

REGENXBIO to Participate in Upcoming Investor Conferences

March 8, 2024 | realmoney.thestreet.com

RBC Capital gets more bullish on Regenxbio, upgrades shares

March 8, 2024 | realmoney.thestreet.com

RBC Capital upgrades Regenxbio to Outperform, sees positive risk-reward

March 8, 2024 | msn.com

Regenxbio raised to Buy at RBC on pivot to Duchenne

March 8, 2024 | markets.businessinsider.com

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO

March 8, 2024 | finance.yahoo.com

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares

March 7, 2024 | finance.yahoo.com

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates

March 7, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA)

March 6, 2024 | prnewswire.com

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

March 6, 2024 | benzinga.com

Latest News for Regenxbio Stock (NASDAQ:RGNX)

See More Headlines

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:RGNX
CUSIP: N/A
CIK: 1590877
Web: www.regenxbio.com
Phone: (240) 552-8181
Fax: N/A
Employees: 344
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $38.45
High Stock Price Target: $55.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +136.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-263,490,000.00
Net Margins: -291.99%
Pretax Margin: -292.15%
Return on Equity: -68.18%
Return on Assets: -39.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.57
Quick Ratio: 2.57

Sales & Book Value

Annual Sales: $90.24 million
Price / Sales: 8.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.09 per share
Price / Book: 2.29

Miscellaneous

Outstanding Shares: 49,040,000
Free Float: 42,604,000
Market Cap: $797.39 million
Optionable: Optionable
Beta: 1.29

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Kenneth T. Mills (Age 49)
President, CEO & Director
Comp: $1.02M
Mr. Vittal K. Vasista (Age 56)
Executive VP & CFO
Comp: $671.41k
Mr. Curran M. Simpson M.S. (Age 62)
Executive VP & COO
Comp: $677.7k
Dr. Olivier Danos Ph.D. (Age 66)
Executive VP & Chief Scientific Officer
Comp: $728.06k
Dr. Stephen Pakola M.D. (Age 55)
Executive VP & Chief Medical Officer
Comp: $673.76k
Mr. Patrick J. Christmas II (Age 53)
J.D., Executive VP & Chief Legal Officer
Comp: $1.11M
Ms. Shiva G. Fritsch
Chief Communications & People Officer
Dr. Laura A. Coruzzi J.D. (Age 70)
Ph.D., Executive Vice President of Intellectual Property
Dr. Ram Palanki Pharm.D. (Age 47)
Executive VP of Commercial Strategy & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.
What is REGENXBIO's stock price target for 2024?: 12 Wall Street research analysts have issued 1-year price objectives for REGENXBIO's shares. Their RGNX share price targets range from $21.00 to $55.00. On average, they anticipate the company's stock price to reach $38.45 in the next year. This suggests a possible upside of 138.7% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.
How have RGNX shares performed in 2024?: REGENXBIO's stock was trading at $17.95 on January 1st, 2024. Since then, RGNX shares have decreased by 10.3% and is now trading at $16.11.
View the best growth stocks for 2024 here.
When is REGENXBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our RGNX earnings forecast.
How were REGENXBIO's earnings last quarter?: REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by $0.16. The biotechnology company earned $22.30 million during the quarter, compared to the consensus estimate of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative trailing twelve-month return on equity of 68.18%. The company's quarterly revenue was down 28.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.38) earnings per share.
What ETFs hold REGENXBIO's stock?: ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and WisdomTree BioRevolution Fund (WDNA).Harbor Disruptive Innovation ETF (INNO).

What is Ken Mills' approval rating as REGENXBIO's CEO?: 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.
What other stocks do shareholders of REGENXBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).
Who are REGENXBIO's major shareholders?: REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.22%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Allan M Fox, Kenneth T Mills, Kenneth T Mills, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.
How do I buy shares of REGENXBIO?: Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RGNX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial